Skip to main content
AmgenRevenue

AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

What happened

Amgen reported total product sales of $9.537 billion for the second quarter of 2026, a 9% increase year-over-year.

Source

Article excerpt

THOUSAND OAKS, Calif., Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2026. "Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales. As we expand the potential of our existing medicines through new indications and advance the next wave of pipeline molecules through Phase 3, we remain confident in our ability to deliver growth well into the next decade," said Robert A. Bradway, chairman and chief executive officer. Key results include: References in this release to "non-GAAP" measures, measures presented "on a non-GAAP basis," and "free cash flow" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion. Product Sales Performance General Medicine Rare Disease Inflammation Oncology Established Products Product Sales Detail by Product and Geographic Region $Millions, except percentages Q2 '26 Q2 '25 YOY Δ U.S ROW TOTAL TOTAL TOTAL Repatha ® $ 510 $ 443 $ 953 $ 696 37 % EVENITY ® 550 164 714 518 38 % Prolia ® 478 281 759 1,122 (32 %) TEPEZZA ® 520 56 576...

Keep reading with a free account

The rest of this article, and every signal for Amgen, is in your free account.

Extracted from this sentence

Total product sales $ 6,990 $ 2,547 $ 9,537 $ 8,771 9 %

Extracted by Autobound

From the Signal API record
Event
Revenue

What this signalsRevenue results often set the next budget cycle.

Amount named
$9.5B
Location
Thousand Oaks, California, United States

More revenue signals at other companies

The full record

From the Signal API record

Numbers

Amount named in the story
$9.5B

Extraction

Confidence
95%
Detected
Aug 4, 2026
signal_type
news
signal_subtype
has_revenue

Use this data

Get every revenue signal for Amgen and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Amgen this week?”

  2. Send it to your own tools

    The Signal API returns revenue signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/cb5c65ba-c03a-3e3b-1930-c5203c0fdfd1 returns this record as JSON. POST /v1/companies/enrich returns every signal for amgen.com.

{
  "signal_id": "cb5c65ba-c03a-3e3b-1930-c5203c0fdfd1",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-08-04T20:01:00+00:00",
  "company": {
    "name": "Amgen",
    "domain": "amgen.com"
  },
  "data": {
    "url": "https://www.prnewswire.com/news-releases/amgen-reports-second-quarter-2026-financial-results-302842890.html",
    "title": "AMGEN REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS",
    "excerpt": "THOUSAND OAKS, Calif. , Aug. 4, 2026 /PRNewswire/ -- Amgen (NASDAQ: AMGN ) today announced financial results for the second quarter of 2026. \"Our results demonstrate strong performance across our business. Our six key growth drivers grew 26% year over year, generating nearly 70% of second-quarter product sales. As we expand the potential of our existing medicines through new indications and advance the next wave of pipeline molecules through Phase 3, we remain confident in our ability to deliver growth well into the next decade,\" said Robert A. Bradway, chairman and chief executive officer. Key results include: References in this release to \"non-GAAP\" measures, measures presented \"on a non-GAAP basis,\" and \"free cash flow\" (computed by subtracting capital expenditures from operating cash flow) refer to non-GAAP financial measures. Adjustments to the most directly comparable GAAP financial measures and other items are presented on the attached reconciliations. Refer to Non-GAAP Financial Measures below for further discussion. Product Sales Performance General Medicine Rare Disease Inflammation Oncology Established Products Product Sales Detail by Product and Geographic Region $Millions, except percentages Q2 '26 Q2 '25 YOY Δ U.S ROW TOTAL TOTAL TOTAL Repatha ® $ 510 $ 443 $ 953 $ 696 37 % EVENITY ® 550 164 714 518 38 % Prolia ® 478 281 759 1,122 (32 %) TEPEZZA ® 520 56 576 505...",
    "summary": "Amgen reported total product sales of $9.537 billion for the second quarter of 2026, a 9% increase year-over-year.",
    "location": "Thousand Oaks, California, USA",
    "planning": false,
    "image_url": "https://mmx.prnewswire.com/media/MS352354/AMGEN-LOGO-V2.jpg?id=OA2823442&p=facebook",
    "confidence": 0.95,
    "published_at": "2026-08-04T20:01:00Z",
    "location_data": [
      {
        "city": "Thousand Oaks",
        "state": "California",
        "region": "Northern America",
        "country": "United States",
        "continent": "Americas",
        "fuzzy_match": false
      }
    ],
    "article_sentence": "Total product sales $ 6,990 $ 2,547 $ 9,537 $ 8,771 9 %",
    "amount_normalized": 9537000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.